Every round on record, with the sources behind each and the investors on them.
An emerging medtech company focused on complex tissue healing
piomic.comZurichMedtechFounded 2016
5 sources · checked 1 time, last 10d ago
The company release and Startupticker date the announcement to 18 September; GS MedTech is dated September 21 and uses $25M, while the company's USD 25 million wording controls.
Publication audit: dropped 1 page(s) about another round
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source's heading states the amount as “CHF 7.5M,” while the body contains the apparent typo “CHFM 7.5”; the heading is used. The SERI-funded EIC Accelerator Grant is described as participation through a grant, not as an investor, so it is omitted from the investor lists.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release states the seed round and publication date but names no amount, investors, or headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Growth | $25M | 2026-09-18 | Swisscanto | No recent discussion |
5 sources · checked 1 time, last 10d ago [ VERIFIED · CORRECTED ] read against 4 of 5 sources
The company release and Startupticker date the announcement to 18 September; GS MedTech is dated September 21 and uses $25M, while the company's USD 25 million wording controls. Publication audit: dropped 1 page(s) about another round | ||||
Piomic Medical builds portable, non-invasive COMS devices that combine optical and magnetic stimulation to help hospitals, clinics and home-care users treat hard-to-heal wounds.
Piomic targets hard-to-heal wounds, which its pages describe as a major healthcare burden, with a portable COMS therapy that combines optical and magnetic stimulation for hospital, outpatient and home-care use. After reporting more than 5,000 treatments and 450 patients in its initial soft launch, the company raised a USD 25 million growth financing to complete the MAVERICKS and NAZARÉ clinical programs, pursue U.S. approval and expand the platform.
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $7.8M CHF 7.5 million | 2022-07-29 | Swiss Diabetes Venture Fund (SDVF) | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source's heading states the amount as “CHF 7.5M,” while the body contains the apparent typo “CHFM 7.5”; the heading is used. The SERI-funded EIC Accelerator Grant is described as participation through a grant, not as an investor, so it is omitted from the investor lists. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: verve.vc·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
| Seed [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | n/a | 2018-04-26 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release states the seed round and publication date but names no amount, investors, or headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: piomic.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: EIC Accelerator Grant, Eurostars